LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

Kodu・Aktsiate loetelu・Coherus Oncology Inc

Coherus Oncology Inc

Avatud

SektorTervishoid

1.53 4.08

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.47

Max

1.55

Põhinäitajad
By Trading Economics
Sissetulek	-278M -37M
Müük	-438K 12M
P/E Sektori keskmine	3.509 49.701
Aktsiakasum	-0.281
Kasumimarginaal	-300.041
Töötajad	145
EBITDA	7.9M -35M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+457.43% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-29M 230M
Eelmine avamishind	-2.55
Eelmine sulgemishind	1.53

Uudiste sentiment

By Acuity

50%

174 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

0.9209 / 1.05 Toetus ja vastupanu

Coherus Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. mai 2026, 20:36 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19. mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19. mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19. mai 2026, 23:28 UTC

Market Talk

Tulu

Global Forex and Fixed Income Roundup: Market Talk

19. mai 2026, 23:28 UTC

Market Talk

Tulu

F&P Healthcare's Outlook Key for Investors -- Market Talk

19. mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19. mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19. mai 2026, 22:02 UTC

Tulu

ZTO Express (Cayman): Di Xu to Resign From Board

19. mai 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19. mai 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19. mai 2026, 22:00 UTC

Tulu

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19. mai 2026, 21:37 UTC

Tulu

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19. mai 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19. mai 2026, 21:01 UTC

Tulu

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19. mai 2026, 20:58 UTC

Tulu

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19. mai 2026, 20:46 UTC

Kuumad aktsiad

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19. mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19. mai 2026, 20:34 UTC

Tulu

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries 4Q EPS 5c >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries 4Q Sales $1.4B >JHX

19. mai 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Buy Empower Semiconductor for $1.5B

19. mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19. mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19. mai 2026, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19. mai 2026, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19. mai 2026, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19. mai 2026, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19. mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Coherus Oncology Inc Prognoos

Hinnasiht

By TipRanks

457.43% tõus

12 kuu keskmine prognoos

Keskmine 8.25 USD 457.43%

Kõrge 12 USD

Madal 4 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Coherus Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Coherus Oncology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9209 / 1.05Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

174 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.